In the global race for a SARS CoV-2 vaccine, scientists at Thomas Jefferson University are working on an
approach that will utilize an existing rabies vaccine as a carrier for the SARS-CoV-2 antigen by taking
advantage of the benefit that the ‘carrier’ vaccine has already been rigorously tested and shown to be safe
and effective. Next to fighting the current SARS CoV-2 pandemic, this dual vaccine candidate may do its
part in solving another serious public health problem in African and Asian countries – ending human
dog-mediated rabies by 2030.

Read more here: Link